Retour sur lavenir.net
   AB INBEV 60.740 € (+1,71 %)     LOTUS BAKERIES 9 900.000 € (+1,64 %)     AGEAS 64.350 € (+2,06 %)     D'IETEREN GROUP 164.600 € (+4,05 %)     KINEPOLIS GROUP 26.500 € (+1,73 %)     KBC 109.850 € (+5,12 %)     ARGENX SE 645.800 € (+4,03 %)     SOFINA 214.800 € (+3,27 %)     IBA 13.100 € (+0,92 %)     AEDIFICA 71.100 € (+2,38 %)     UMICORE 16.580 € (+2,47 %)     MONTEA 67.200 € (+2,75 %)     OXURION 0.006 € (0,00 %)     ENERGYVISION 12.470 € (+0,16 %)     IMMOBEL 21.500 € (+5,91 %)     ORANGE BELGIUM 20.500 € (+1,49 %)     SIPEF 97.400 € (-2,01 %)     ONTEX GROUP 3.325 € (-7,51 %)     CARE PROPERTY INV. 12.380 € (+0,98 %)     VASTNED 29.600 € (+2,42 %)     VGP 86.900 € (+5,85 %)     COFINIMMO 83.350 € (+2,65 %)     FAGRON 21.800 € (+0,93 %)     ACKERMANS V.HAAREN 271.200 € (+3,27 %)     ROULARTA 12.700 € (0,00 %)     HOME INVEST BE. 18.480 € (+0,43 %)     DEME GROUP 191.000 € (+3,58 %)     BELYSSE GROUP 0.620 € (+5,08 %)     COLRUYT 35.320 € (-2,65 %)     EVS BROADC.EQUIPM. 34.250 € (+2,85 %)     CMB.TECH 10.920 € (-0,18 %)     TUBIZE-FIN 218.000 € (+2,83 %)     MELEXIS 54.850 € (+4,38 %)     SYENSQO 49.310 € (-0,34 %)     ELIA GROUP 134.000 € (+1,67 %)     SHURGARD 25.650 € (+3,22 %)     WDP 23.300 € (+4,39 %)     ASCENCIO 48.700 € (-2,79 %)     JENSEN-GROUP 67.000 € (+5,68 %)     VAN DE VELDE 30.700 € (+1,32 %)     TINC 11.640 € (+1,75 %)     PROXIMUS 7.090 € (+1,29 %)     CAMPINE 195.000 € (0,00 %)     SOLVAY 26.740 € (+1,06 %)     UCB 267.800 € (+3,60 %)     DECEUNINCK 2.065 € (+3,46 %)     BPOST 1.858 € (+3,80 %)     AZELIS GROUP 8.760 € (+0,92 %)     GIMV 45.700 € (+1,22 %)     TITAN S.A. 46.950 € (+4,45 %)     RECTICEL 9.820 € (+3,92 %)     AGFA-GEVAERT 0.489 € (+6,07 %)     GBL 78.550 € (+1,03 %)     CELYAD ONCOLOGY 0.314 € (-1,88 %)     BARCO 9.515 € (+0,53 %)     BEKAERT 40.600 € (+1,50 %)     ONWARD MEDICAL 3.415 € (+3,02 %)     VIOHALCO 13.200 € (+3,12 %)     FLUXYS BELGIUM D 21.500 € (+2,87 %)     TESSENDERLO 20.650 € (+5,46 %)  
   ARKEMA 59.050 € (+1,29 %)     CREDIT AGRICOLE 16.580 € (+4,08 %)     ASML HOLDING 1 187.600 € (+6,11 %)     INPOST 15.120 € (+0,27 %)     AEGON 6.394 € (+2,67 %)     AIRBUS 167.900 € (+4,40 %)     IPSOS 34.500 € (+2,56 %)     ATOS 35.840 € (+6,19 %)     LUMIBIRD 21.800 € (+5,83 %)     ARCADIS 28.540 € (+4,08 %)     AIR FRANCE -KLM 9.322 € (+8,93 %)     TOTALENERGIES 77.560 € (-4,14 %)     STMICROELECTRONICS 29.935 € (+4,65 %)     E PANGO 0.270 € (+0,37 %)     BNP PARIBAS ACT.A 85.380 € (+5,42 %)     2CRSI 29.350 € (+5,20 %)     KPN KON 4.769 € (-0,71 %)     CEGEDIM 12.250 € (+4,70 %)     UNILEVER 48.300 € (-0,66 %)     RELX 28.740 € (+0,42 %)     VALLOUREC 21.570 € (-0,83 %)     ADP 109.200 € (+4,40 %)     SHELL PLC 39.525 € (-3,73 %)     ARCELORMITTAL SA 46.660 € (+6,43 %)     SOCIETE GENERALE 65.960 € (+6,80 %)     IPSEN 165.100 € (+2,93 %)     PROSUS 40.530 € (+3,98 %)     LACROIX GROUP 13.200 € (+5,18 %)     MAGNUM 12.480 € (-1,81 %)     EMEIS 13.870 € (+6,37 %)     KERING 263.200 € (+2,57 %)     RUBIS 34.860 € (+1,16 %)     ORANGE 17.675 € (0,00 %)     PUBLICIS GROUPE SA 71.280 € (+0,62 %)     ALLFUNDS GROUP 8.550 € (+0,29 %)     BUREAU VERITAS 26.240 € (+2,10 %)     SAFRAN 290.600 € (+4,01 %)     AKZO NOBEL 50.900 € (+3,46 %)     HEIJMANS KON 80.500 € (+5,09 %)     VEOLIA ENVIRON. 33.080 € (+1,29 %)     MAROC TELECOM 9.300 € (+2,20 %)     BAIKOWSKI 19.700 € (-1,01 %)     VALNEVA 2.822 € (+0,07 %)     ADYEN 863.700 € (+1,54 %)     INTERPARFUMS 23.300 € (+2,01 %)     IMCD 88.740 € (-0,85 %)     ESSILORLUXOTTICA 193.950 € (-2,24 %)     PHARMING GROUP 1.459 € (+1,74 %)     Vusion 111.100 € (+1,46 %)     EURAZEO 41.700 € (+3,22 %)     THALES 266.500 € (+5,71 %)     BOIRON 27.700 € (+2,59 %)     NN GROUP 69.280 € (+3,31 %)     EXAIL TECHNOLOGIES 131.000 € (+10,08 %)     SAINT GOBAIN 72.180 € (+3,03 %)     MICHELIN 29.910 € (+2,47 %)     LVMH 471.100 € (+1,73 %)     AHOLD DEL 41.200 € (+2,26 %)     SCHNEIDER ELECTRIC 239.950 € (+4,74 %)     SANOFI 82.870 € (+0,18 %)  
News Réglementées
31/03/2026 11:40

Fosun International: Total Revenue in 2025 Reaches RMB173.43 Billion, with Overseas Revenue Accounting for 54.7%, Aiming to Achieve"RMB10 Billion in Profit"

EQS-News: Fosun / Key word(s): Annual Results
Fosun International: Total Revenue in 2025 Reaches RMB173.43 Billion, with Overseas Revenue Accounting for 54.7%, Aiming to Achieve"RMB10 Billion in Profit"

31.03.2026 / 11:40 CET/CEST
The issuer is solely responsible for the content of this announcement.


HONG KONG, March 31, 2026 /PRNewswire/ -- On 30 March, Fosun International (00656.HK) announced its results for the 12 months ended 31 December 2025. In 2025, Fosun's fundamentals remained solid, core industries such as pharmaceuticals and healthcare and insurance and finance demonstrated a good development trend, and the twin drivers of innovation and globalization delivered strong momentum.

During the Reporting Period, the Group's total revenue reached RMB173.43 billion, and adjusted industrial operation profit amounted to RMB4 billion. The four core subsidiaries generated RMB128.2 billion in revenue, accounting for 74% of the Group's total revenue. Among them, Fosun Pharma, a core subsidiary in the Health segment, achieved a net profit attributable to shareholders of the parent of RMB3.371 billion, representing a year-on-year increase of 21.69%; Fosun Insurance Portugal, a core subsidiary in the Wealth segment, reported a net profit attributable to owners of the parent of EUR201 million, up 15.8% year on year.

During the Reporting Period, the Group's investment in technology innovation reached RMB7.8 billion, and 16 indications of 7 innovative drugs were approved for marketing in China and overseas markets. In addition, nearly 40 innovative drug clinical trials were approved by regulatory authorities in China, the United States and Europe, while multiple core products entered key clinical phases, laying a solid pipeline foundation for subsequent commercial growth.

During the Reporting Period, the Group's overseas revenue reached RMB94.86 billion, accounting for 54.7% of total revenue, representing a year-on-year increase of 5.4 percentage points. For innovative drugs, total upfront payments from licensing-out and co-development for the year exceeded USD260 million, with total potential milestone payments exceeding USD4 billion.

Club Med, a subsidiary of Fosun Tourism Group, has sales and marketing operations in more than 40 countries and regions across six continents, and operates 67 resorts. During the Reporting Period, Club Med once again achieved record‑high performance, with revenue reaching RMB17.97 billion, representing a year-on-year increase of 2.1%. Its global average room occupancy rate reached 75.8%, up 1.8 percentage points, while the average daily bed rate rose to RMB1,948.9, up 3.0% from 2024. This 75-year-old brand will continue to fulfill its mission of "Better Holiday, Better Life," enhance its global operational capabilities, and further accelerate its global growth.

Fosun has continued to advance its strategy of "streamlining operations and strengthening the business, focusing on core businesses". During the Reporting Period, pursuant to the principle of prudence, Fosun made non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments, resulting in a book loss of RMB23.4 billion for the year, of which real estate-related impairment accounted for approximately 55%, while impairment of non-core assets accounted for approximately 45%. These provisions do not affect the Company's overall operations and cash flow.

In his letter to shareholders, Guo Guangchang, Chairman of Fosun International, stated: "Some of the projects we invested in years ago are now indeed valued differently under current market conditions from what we expected at the time of investment. Accordingly, the Board has prudently chosen to complete this asset impairment, allowing Fosun to better concentrate its resources and efforts on high-growth core sectors. As the global economy presents opportunities amid fluctuations and China's innovation industry gains momentum, deepening our strategic focus now allows us not only to optimize our asset structure, but also to seize industry opportunities, positioning Fosun as a leaner, healthier, and more sustainable company."

At the same time, Fosun has maintained a healthy financial position, with ample cash reserves, a solid net asset base, and positive net cash inflow from operating activities. As at the end of the Reporting Period, total debt to total capital ratio was 57%; in addition to cash, bank balances and term deposits of RMB61.1 billion, unutilized banking facilities amounted to RMB144.6 billion. A healthy debt ratio and ample funds not only strengthen the Company's risk resilience, but also enhance its capacity to seize opportunities. International rating agency S&P has affirmed the outlook for Fosun International's credit rating as "Stable".

"It is precisely this strong foundation, together with the continued support of our partners, that gives us the confidence and determination to 'repair the roof while the sun is shining' — to shed burdens at this stage and pursue predictable, sustainable growth for the future. We must strengthen our core businesses with greater focus and depth. This is the path for Fosun to move more steadily and go further in the next phase," said Guo Guangchang.

Fosun also announced its medium-term financial targets: to strive to gradually restore annual profit to around RMB10 billion; to target the recovery of RMB60 billion in cash at the Group level, reduce total Group-level debt to below RMB60 billion, and work to achieve an "investment-grade" rating.

In terms of further enhancing shareholder returns, in addition to share purchases by the controlling shareholder and management, as well as the Company's continued share buybacks, Fosun announced that it plans to increase its target dividend payout ratio for the 2026 financial year from the current 20% to 35%, and is committed to further raising the payout ratio over time. Based on the Company's accumulated distributable profits, dividends for the 2026 financial year are expected to be no less than HKD1.5 billion.

"For the future, Fosun will not pursue short-term gains; instead, we will build a solid foundation for enduring growth," said Guo Guangchang.

Cision View original content:https://www.prnewswire.co.uk/news-releases/fosun-international-total-revenue-in-2025-reaches-rmb173-43-billion-with-overseas-revenue-accounting-for-54-7-aiming-to-achievermb10-billion-in-profit-302729793.html

rt.gif?NewsItemId=EN23460&Transmission_Id=202603310536PR_NEWS_EURO_ND__EN23460&DateId=20260331


31.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2301360  31.03.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière